Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001221400 | SCV001393443 | uncertain significance | not provided | 2022-06-13 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 4323 of the USH2A protein (p.Leu4323Phe). This variant is present in population databases (rs750512832, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with USH2A-related conditions. ClinVar contains an entry for this variant (Variation ID: 949836). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002504277 | SCV002816588 | uncertain significance | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2021-11-12 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003449697 | SCV004181922 | uncertain significance | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001828765 | SCV004181923 | uncertain significance | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001828765 | SCV002088284 | uncertain significance | Usher syndrome type 2A | 2020-04-20 | no assertion criteria provided | clinical testing |